AC Immune Reports Third Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/08/21
Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to DeclineZacks Investment Research • 11/05/21
AC Immune Extends Research Collaboration with University of Pennsylvania Focusing on the Pathogenic Protein TDP-43, a Major Driver of Neurodegenerative DiseasesGlobeNewsWire • 11/04/21
New Data on AC Immune's Abeta and pTau Clinical Programs in Alzheimer's Disease To Be Presented at CTAD 2021GlobeNewsWire • 11/02/21
AC Immune Holds its Extraordinary General Meeting and Appoints Monica Shaw, M.D., and Prof.GlobeNewsWire • 10/29/21
AC Immune CEO Andrea Pfeifer Receives First SEF.WomenAward for CEO of the YearGlobeNewsWire • 09/03/21
AC Immune to Participate in Upcoming Virtual Investor Conferences in SeptemberGlobeNewsWire • 09/02/21
AC Immune Announces First Positive Cognitive Results for a Tau-Targeting Monoclonal Antibody in Alzheimer's DiseaseGlobeNewsWire • 08/31/21
AC Immune Reports Second Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/04/21
AC Immune Presents Full Phase 1b Results on Anti-Abeta Vaccine and Discusses its First-in-Class Diagnostic for Parkinson's Disease at AAIC 2021GlobeNewsWire • 07/29/21
Earnings Preview: AC Immune (ACIU) Q2 Earnings Expected to DeclineZacks Investment Research • 07/28/21
AC Immune Secures Funding From BioNTech Investors, Buys Parkinson's Vaccine CandidateBenzinga • 07/27/21
AC Immune acquires AFFiRiS' Specific Active Immunotherapy (SAIT) anti-alpha-synuclein programs targeting neurodegenerative diseasesGlobeNewsWire • 07/27/21
AC Immune Announces Strategic Acquisition of Industry-leading Parkinson's Disease Vaccine Candidate and Equity Investment Led by Athos Service GmbHGlobeNewsWire • 07/27/21